ONXEO

Onxeo is a biotechnology company that develops drugs for oncology. It offers Beleodaq, a histone deactylase inhibitor for the treatment of peripheral T-cell lymphoma; Livatag, a nanoparticle formulation of doxorubicin, which is in Phase III clinical trials for the treatment of primary liver cancer; Validive, a mucoadhesive buccal tablet that is in Phase II clinical trials for the prevention and the treatment of chemoradioation therapy-induced severe oral mucositis in patients with head and neck cancer; and Combo BelCHOP, which is Phase II clinical trials for the treatment of peripheral T-cell lymphoma. Onxeo is headquartered in Paris, France.

#SimilarOrganizations #People #Financial #Event #Website #More

ONXEO

Social Links:

Twitter

Industry:

Biopharma Biotechnology Pharmaceutical

Founded:

1997-01-01

Address:

Paris, Ile-de-France, France

Country:

France

Website Url:

http://www.onxeo.com

Total Employee:

11+

Status:

Active

Contact:

+330145587600

Email Addresses:

[email protected]

Total Funding:

60.4 M EUR

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network Google Universal Analytics

Similar Organizations

not_available_image

Alix

Alix SA is a biotechnology company that develops drugs for the identification of therapeutic targets.

aura-biosciences-logo

Aura Biosciences

Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.

axcella-logo

Axcella

Axcella is a biotechnology company providing therapeutics development solutions.

immutep-logo

Immutep

Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.

prestizia-logo

Prestizia

Prestizia is a biotechnology company that is developing a microRNA1 technology.

reata-pharmaceuticals-logo

Reata Pharmaceuticals

Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.

Current Advisors List

shefali-agarwal_image

Shefali Agarwal Chairwoman of the Board of Director @ Onxeo
Board_member

Current Employees Featured

shefali-agarwal_image

Shefali Agarwal
Shefali Agarwal President & Chief Executive Officer @ Onxeo
President & Chief Executive Officer
2022-01-01

valerie-leroy_image

Valerie Leroy
Valerie Leroy Director, Investor Relations & Corporate Communications @ Onxeo
Director, Investor Relations & Corporate Communications
2016-12-01

Founder

gilles-avenard_image

Gilles Avenard

Stock Details

Company's stock symbol is EPA:ONXEO

Acquisitions List

Date	Company	Article	Price
2016-02-29	DNA Therapeutics	DNA Therapeutics acquired by Onxeo	1.85 M USD
2007-06-27	TopoTarget Switzerland	TopoTarget Switzerland acquired by Onxeo	N/A
2002-06-04	TopoTarget UK Limited	TopoTarget UK Limited acquired by Onxeo	N/A

Investors List

invus_image

Key Employee Changes

Date	New article
2022-04-07	Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer
2022-01-03	Onxeo Appoints Julien Miara as New Interim CEO

Official Site Inspections

http://www.onxeo.com Semrush global rank: 5.13 M Semrush visits lastest month: 1.59 K

Host Informations
Whois Informations

Loading ...